Combipatch is a drug owned by Noven Pharmaceuticals Inc. It is protected by 4 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 12, 2014. Details of Combipatch's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5656286 | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
Aug, 2014
(10 years ago) |
Expired
|
| US6024976 | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
Jan, 2014
(10 years ago) |
Expired
|
| US5958446 | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
Dec, 2012
(11 years ago) |
Expired
|
| US5474783 | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
Dec, 2012
(11 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Combipatch is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Combipatch's family patents as well as insights into ongoing legal events on those patents.
Combipatch's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Combipatch's generic launch date based on the expiry of its last outstanding patent is estimated to be Aug 12, 2014 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Combipatch Generic API suppliers:
Estradiol; Norethindrone Acetate is the generic name for the brand Combipatch. 8 different companies have already filed for the generic of Combipatch, with Aurobindo Pharma Ltd having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Combipatch's generic
Alternative Brands for Combipatch
There are several other brand drugs using the same active ingredient (Estradiol; Norethindrone Acetate) as Combipatch. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||||
|---|---|---|---|---|---|
| Apil |
| ||||
| Sumitomo Pharma |
| ||||
| Teva Branded Pharm |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Estradiol; Norethindrone Acetate, Combipatch's active ingredient. Check the complete list of approved generic manufacturers for Combipatch
About Combipatch
Combipatch is a drug owned by Noven Pharmaceuticals Inc. Combipatch uses Estradiol; Norethindrone Acetate as an active ingredient. Combipatch was launched by Noven Pharms Inc in 1998.
Approval Date:
Combipatch was approved by FDA for market use on 07 August, 1998.
Active Ingredient:
Combipatch uses Estradiol; Norethindrone Acetate as the active ingredient. Check out other Drugs and Companies using Estradiol; Norethindrone Acetate ingredient
Dosage:
Combipatch is available in film, extended release form for transdermal use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.05MG/24HR;0.14MG/24HR | FILM, EXTENDED RELEASE | Prescription | TRANSDERMAL |
| 0.05MG/24HR;0.25MG/24HR | FILM, EXTENDED RELEASE | Prescription | TRANSDERMAL |